Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

75.01 -0.26 (-0.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,351,921
Open 74.76
Bid (Size) 74.60 (2)
Ask (Size) 75.74 (5)
Prev. Close 75.27
Today's Range 74.35 - 75.61
52wk Range 61.45 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.79%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
How Is The Market Feeling About Gilead Sciences?
Via Benzinga
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Many stocks have nosebleed valuations. But not these. 
Via The Motley Fool

Performance

YTD
-12.16%
-12.16%
1 Month
-1.73%
-1.73%
3 Month
-2.02%
-2.02%
6 Month
-5.74%
-5.74%
1 Year
+19.33%
+19.33%

More News

Read More
Gilead Sciences Unusual Options Activity
Via Benzinga
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
From Gilead Sciences, Inc.
Via Business Wire
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Via The Motley Fool
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today
Via Benzinga
Where Gilead Sciences Stands With Analysts
Via Benzinga
(GILD) - Analyzing Gilead Sciences's Short Interest
Via Benzinga
Can These 3 Healthcare Dividend Stocks Deliver Income Growth?
Via MarketBeat
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
Via FinancialNewsMedia
Exposures Product Safety
Time For Gilead Sciences-Heavy ETFs?
Via Talk Markets
Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment
Via Benzinga
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
What You Need to Know About Hepatitis C This Recovery Month
Via Brandpoint
Exposures COVID-19
How To Earn $500 A Month From Gilead Sciences Stock
Via Benzinga
Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades
Via Benzinga
The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month
Via Investor's Business Daily
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
Via Benzinga
Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Gilead Prices $2 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
3 No-Brainer Dividend Stocks to Buy in September
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.